Global Cancer Biologics Market 2025-2029

Cancer Biologics Market 2025-2029

The cancer biologics market is forecasted to grow by USD 84.5 billion during 2024-2029, accelerating at a CAGR of 10.7% during the forecast period. The report on the cancer biologics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global incidence of cancer, increased demand for cancer biologics due to emphasis on personalized medicines, and significant therapeutic benefits of cancer biologics.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's cancer biologics market is segmented as below:

By Product

• Monoclonal antibodies
• Cell and gene therapy
• Vaccines
• Others

By Route Of Administration

• Injectable
• Oral

By Type

• Breast cancer
• Lung cancer
• Colorectal cancer
• Prostate cancer
• Others

By Distribution Channel

• Hospitals
• Clinics
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the untapped potential of cancer biologics in developing countries as one of the prime reasons driving the cancer biologics market growth during the next few years. Also, rise in research and development for development of innovative cancer biologics and increased use of predictive biomarkers will lead to sizable demand in the market.

The report on the cancer biologics market covers the following areas:

• Cancer Biologics Market sizing
• Cancer Biologics Market forecast
• Cancer Biologics Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer biologics market vendors that include Amgen Inc., AstraZeneca PLC, Bayer AG, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Co. Ltd., Cipla Inc., DR Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Jazz Pharmaceuticals PLC, Johnson and Johnson Services Inc., Lupin Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., and Viatris Inc.. Also, the cancer biologics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.